Clinical issues and research in respiratory failure from severe acute respiratory syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 171, Issue 5, 2005, Pages 518-526

  Levy, Mitchell M ^b   Baylor, Melisse S ^b   Bernard, Gordon R ^b   Fowler, Rob ^b   Franks, Teri J ^b   Hayden, Frederick G ^b   Helfand, Rita ^b   Lapinsky, Stephen E ^b   Martin, Thomas R ^b   Niederman, Michael S ^b   Rubenfeld, Gordon D ^b   Slutsky, Arthur S ^b   Stewart, Thomas E ^b   Styrt, Barbara A ^b   Thompson, B Taylor ^b   Harabin, Andrea L ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NONE

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Infectious disease

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IMMUNOMODULATING AGENT; METHYLPREDNISOLONE; PREDNISONE; PROTEINASE INHIBITOR; RIBAVIRIN;

ACUTE LUNG INJURY; ARTIFICIAL VENTILATION; BODY POSITION; CANADA; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; HEALTH CARE PLANNING; HUMAN; HUMIDIFIER; INFECTION CONTROL; INFORMATION PROCESSING; INTENSIVE CARE UNIT; INTERPERSONAL COMMUNICATION; LEADERSHIP; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL RESEARCH; MORALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; RESPIRATORY FAILURE; RISK BENEFIT ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; STRESS ULCER; TIDAL VOLUME; VENOUS THROMBOEMBOLISM; WORKSHOP;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; CANADA; CLINICAL PROTOCOLS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INFECTION CONTROL; LUNG; PNEUMONIA; PULMONARY DISEASE (SPECIALTY); RESEARCH; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; SEVERE ACUTE RESPIRATORY SYNDROME; UNITED STATES;

EID: 20144389859     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200405-621WS     Document Type: Conference Paper

References (88)

1. Dellinger RP, Cartel JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving sepsis campaign for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-873.
2. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 (revised 26 September 2003). Accessed October 29, 2003. Available from URL: http://www.who.int/csr/SARS/ country/table2003_09_23/en/
3. World Health Organization. Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome. Available online at: http://www.who.int/csr/ SARS/en/WHOconsensus.pdf [Last accessed October 29, 2003.]
4. Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC, Se-Thoe SY, Oon L, Bai X, Stanton L, et al. Laboratory-acquired severe acute respiratory distress syndrome. N Engl J Med 2004;350:1740-1745.
5. Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H, Walmsley S, Mazzulli T, Avendana M, Derkach P, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-2809.
6. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, Stewart TE for the Toronto SARS Critical Care Group. Critically ill patients with severe acute respiratory syndrome. JAMA 2003;290:367-373.
7. Lew TWK, Kwek T-K, Tai D, Earnest A, Loo S, Singh K, Kwan KM, Chan Y, Yim CF, Bek SL, Kor AC, et al. Acute respiratory distress syndrome in critically Ill patients with severe acute respiratory distress syndrome. JAMA 2003;290:374-380.
8. Shek CC, Ng PC, Fung GPG, Cheng FWT, Chan PKS, Peiris MJS, Lee KH, Wong SF, Cheung HM, Li AM, et al. Infants born to mothers with severe acute respiratory syndrome. Pediatrics 2003;112:e254-e256.
9. Jernigan JA, Low DE, Helfand RF. Combining clinical and epidemiologic features for early recognition of SARS. Emerg Infect Dis 2004;10:327-333.
10. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, Tellier R, Draker R, Adachi D, Ayers M, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
11. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, et al. A major outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med 2003;348:1986-1994.
12. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, Selbs E, McEvoy PL, Hayden DL, Fukuoka J, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 2003;34:743-748.
13. Armed Forces Institute of Pathology. SARS. Available online at: http://www.afip.org/Departments/Pulmonary/SARS/ [Last accessed January 24, 2005]
14. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003;361:2045-2046.
15. He M-L, Zheng B, Peng Y, Peiris JSM, Poon LLM, Yuen KY, Lin MCM, Kung H-F, Guan Y. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 2003;290:2665-2666.
16. Mathews DA, Patick AK, Baker RO, Brothers MA, Dragovich PS, Hartmann CJ, Johnson TO, Mucker EM, Reich SH, Rejto PA, et al. In vitro antiviral activity of human rhinovirus 3C protease inhibitors against the SARS coronavirus. In: Knobler S, Mahmoud A, Lemon S, Mack A. Sivitz L, Oberholtzer K, editors. Learning from SARS: preparing for the next disease outbreak - workshop summary. Washington, DC: Institute of Medicine, The National Academies Press; 2004. pp. 19-29.
17. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, Kao RYT, Poon LLM, Wong CLP, Guan Y, et al. on behalf of the HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-256.
18. Liu S, Xiao G, Chen Y, He U, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 2004;363:938-947.
19. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003;362:293-294.
20. Hensley LE, Fritz EA, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10:317-319.
21. Haagmans BL, Kuiken T, Martina BE, Fouchier RAM, Rimmelzwaan GF, van Amerongen G, van Riel D, de Jong T, Itamura S, Chan K-H, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10:290-293.
22. Tan ELC, Ooi EE, Lin C-Y, Tan HC, Ling AI, Lim B, Stanton LW. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004;10:581-586.
23. Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 2004;189:1164-1167.
24. Wu CJ, Jan JT, Chen CM, Hsieh HP, Huang DR, Liu HW, Liu CY, Hwang HW, Chen SC, Hong CF, et al. Inhibition of Severe Acute Respiratory Syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother 2004;48:2693-2696.
25. Sui J, Li W, Murakami A, Tamin A, Mathews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101:2536-2541.
26. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. An efficient method to make human monocloncal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871-875.
27. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003;60:51-59.
28. Tsang OT, Chau TN, Choi KW, Tso EY, Lim W, Chiu MC, Tong WL, Lee PO, Lam BH, Ng TK, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003;9:1381-1387.
29. Centers for Disease Control. Severe Acute Respiratory Syndrome (SARS) and coronavirus testing - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:297-302.
30. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-1772.
31. Mazzulli T, Farcas GA, Poutanen SM, Willey BM, Low DE, Butany J, Asa SL, Kain KC. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis 2004;10:20-24.
32. Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37:1139-1142.
33. Subbarao K, McAuliffe, J, Vogel L, Fahle G, Fischer S, Tati K, Packard M, Shieh WJ, Zaki S, Murphy B. Prior infection an dpassive transfer of neutralizing antibody prevent replication of severe acute respiratory distress syndrome coronavirus in the respiratory tracts of mice. J Virol 2004;78:3572-3577.
34. terMeulen J, Bakker ABH, van den Brink EN, Wevering GJ, Byron EE, Martina BEE, Haagmans BL, Buiken T, Preiser W, Spaan W, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004;363:2139-2141.
35. Fuchizaki U, Kaneko S, Nakamoto Y, Sugiyama Y, Imagawa K, Kikuchi M, Kobayashi K. Synergistic antiviral effect of a combination of mouse interferon-α and interferon-γ on mouse hepatitis virus. J Med Virol 2003;69:188-194.
36. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DAJ. Intranasal Interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983;24:713-715.
37. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. J Infect Dis 1986;54:443-447.
38. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290:3222-3228.
39. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-720.
40. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, et al. Guidelines for the management of adults with community-acquired pneumonia Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-1754.
41. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman M, Torres A. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk and prognosis. Arch Intern Med 2002;162:1849-1858.
42. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084.
43. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-824.
44. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.
45. Fowler RA, Guest CB, Lapinsky SE, Sibbald WJ, Louie M, Tang P, Simor AE, Stewart TE. Transmission of severe acute respiratory syndrome during intubation and mechanical ventilation. Am J Respir Crit Care Med 2004;169:1198-1202.
46. National Heart, Lung, and Blood Institute. NHLBI ARDSnet website. Available online at: http://www.ardsnet.org [Last accessed January 24, 2005]
47. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ, Kariman K, Higgins S, Bradley R, Metz CA, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1566-1570.
48. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 1987;92:1032-1036.
49. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high does methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-68.
50. Weigelt JA, Norcross JF, Borman KR, Synder WH. Early steroid therapy for respiratory failure. Arch Surg 1985;120:536-540.
51. Thompson BT. Glucocorticoids and acute lung injury [review]. Crit Care Med 2003;31:S253-S257.
52. Meduri UG, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley E. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:159-165.
53. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, et al., for the Canadian Critical Care Trials Group. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683-693.
54. De Jonghe B, Sharshar T, Lefaucheur J-P, Authier F-J, Durand-Zaleski I, Boussarsar M, Cerf C, Renaud E, Mesrati F, Carlet J, et al. for the Groupe de Réflexion et d'Etude des Neuromyopathies en Réanimation. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002;288:2859-2867.
55. Ksiazek TG, Erdman D, Goldsmith CS, Zaki S, Peret T, Emery S, Tong S, Urbani C, Comer J, Lim W, et al., and the SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966.
56. Ooi GC, Khong PL, Ho JC, Lam B, Wong WM, Yiu WC, Wong PC, Wong CF, Lai KN, Tsang KWT. Severe Acute Respiratory Syndrome: radiographic evaluation and clinical outcome measures. Radiology 2003;229:500-506.
57. Zhong NS, Zeng GQ. Our strategies for fighting Severe Acute Respiratory Syndrome (SARS). Am J Respir Crit Care Med 2003;168:7-9.
58. Ho JC, Ooi GC, Mok TY, Chan JW, Hung I, Lam B, Wong PC, Li PC, Ho PL, Lam WK, et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003;168:1449-1456.
59. Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. N Engl J Med 2003;348:1947-1948.
60. Bernard GR. Corticosteroids: the "terminator" of all untreatable serious pulmonary illness. Am J Respir Crit Care Med 2003;168:1409-1410.
61. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10:448-450.
62. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-117.
63. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C. Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;41:793-800.
64. Kapoor M, Kupfer Y, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in the critically ill. Crit Care Med 1999;27(12, Suppl)A69.
65. Bresalier RS, Grendell JH, Cello JP, Meyer AA. Sucralfate versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients. Am J Med 1987;83:110-116.
66. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, et al., for The Canadian Critical Care Trials Group. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in p patients requiring mechanical ventilation. N Engl J Med 1998;338:791-797.
67. Kollef MH, Levy NT, Ahrens TS, Schaiff R, Prentice D, Sherman G. The use of continuous IV sedation is associated with prolongation of mechanical ventilation. Chest 1998;114:541-548.
68. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-1477.
69. Brook AD, Ahrens TS, Schaiff R, Prentice D, Sherman G, Shannon W, Kollef M. Effect of a nursing-implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med 1999;27:2609-2615.
70. Giostra E, Magistris MR, Pizzolato G, Cox J, Chevrolet JC. Neuromuscular disorder in intensive care unit patients treated with pancuronium bromide: occurrence in a cluster group of seven patients and two sporadic cases, with electrophysiologic and histologic examination. Chest 1994;106:210-220.
71. Brandom BW, Yellon RF, Lloyd ME, Gronert BJ, Theroux MC, Simhi E, Chakravorti S, Venkataraman S, Dohar JE, Shapiro AM, et al. Recovery from doxacurium infusion administered to produce immobility for more than four days in pediatric patients in the intensive care unit. Anesth Analg 1997;84:307-314.
72. Leatherman JW, Fluegel WL, David WS, Davies SF, Iber C. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996;153:1686-1690.
73. Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J, Hyzy R, Zarowitz B. A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 1997;25:575-583.
74. Frankel H, Jeng J, Tilly E, St Andre A, Champion H. The impact of implementation of neuromuscular blockade monitoring standards in a surgical intensive care unit. Am Surg 1996;62:503-506.
75. Karir V, Polissar, N, Cooper C, Neff, M, Rubenfeld, G, Veberes, L, Day, D, Spencer, T. Lung protective ventilation for acute lung injury does not increase sedation use [abstract]. Crit Care Med 2002;30:A95.
76. Torres A, Serra-Batlles J, Ros E, Piera C, Puig de la Bellacasa J, Cobos A, Lomena F, Rodriguez-Roisin R. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992;116:540-543.
77. Ibanez J, Penafiel A, Marse P, Jorda R, Raurich JM, Mata F. Gastroesophageal reflux in intubated patients receiving enteral nutrition: Effect of supine and semirecumbent positions J Parenter Enteral Nutr 2000;24:103-106.
78. Orozco-Levi M, Torres A, Ferrer M, Piera C, el-Ebiary M, de la Bellacasa JP, Rodriguez-Roisin R. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 1995;152:1387-1390.
79. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogué S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999;354:1851-1858.
80. Lapinsky SE, Hawryluck L. ICU management of severe acute respiratory syndrome. Intensive Care Med 2003;29:870-875.
81. Healthcare Canada. Healthcare Canada Online SARS for Health Professionals. Available online at: http://www.hc-sc.gc.ca/english/protection/ warnings/sars/index.htm [Last accessed January 24, 2005]
82. Mt. Sinai Hospital Critical Care Unit SARS resources. Available online at: http://sars.medtau.org [Last accessed January 24, 2005]
83. Centers for Disease Control Public Health Guidance for Community-Level Preparedness and Response to Severe Acute Respiratory Syndrome (SARS) Version 2. Available online at: http://www.cdc.gov/ncidod/sars/guidance/I/index.htm [Last accessed January 24, 2005]
84. Booth CM, Stewart TE. Communication in the Toronto critical care community: important lessons learned during SARS. Crit Care 2003;7:405-406.
85. Maunder R, Hunter J, Vincent L, Bennett J, Peladeau N, Leszcz M, Sadavoy J, Verhaeghe LM, Steinberg R, Mazzulli T. The immediate psychological and occupational impact of the 2003 SARS outbreak in a teaching hospital. CMAJ 2003;168:1245-1251.
86. Cooper A, Joglekar A, Adhikari N. A practical approach to airway management in patients with SARS. CMAJ 2003;169:785-787.
87. Canadian SARS Research Network. Available online at: http://www. candiansarsresearchnetwork.ca [Last accessed September 21, 2004]
88. Selected resources on SARS Available online at: http://www.lip.cuhk. edu.hk [Last accessed September 21, 2004]